WO2019004733A2 - Composition pour la prévention, le soulagement ou le traitement de la stéatose hépatique, comprenant un extrait de gryllus bimaculatus en tant qu'ingrédient actif - Google Patents

Composition pour la prévention, le soulagement ou le traitement de la stéatose hépatique, comprenant un extrait de gryllus bimaculatus en tant qu'ingrédient actif Download PDF

Info

Publication number
WO2019004733A2
WO2019004733A2 PCT/KR2018/007319 KR2018007319W WO2019004733A2 WO 2019004733 A2 WO2019004733 A2 WO 2019004733A2 KR 2018007319 W KR2018007319 W KR 2018007319W WO 2019004733 A2 WO2019004733 A2 WO 2019004733A2
Authority
WO
WIPO (PCT)
Prior art keywords
cricket
fatty liver
liver disease
extract
active ingredient
Prior art date
Application number
PCT/KR2018/007319
Other languages
English (en)
Korean (ko)
Other versions
WO2019004733A3 (fr
Inventor
채성욱
임아랑
김기모
Original Assignee
한국 한의학 연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020170181808A external-priority patent/KR102085577B1/ko
Application filed by 한국 한의학 연구원 filed Critical 한국 한의학 연구원
Publication of WO2019004733A2 publication Critical patent/WO2019004733A2/fr
Publication of WO2019004733A3 publication Critical patent/WO2019004733A3/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/20—Animal feeding-stuffs from material of animal origin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives

Definitions

  • the present invention relates to a composition for preventing, ameliorating or treating a fatty liver disease comprising a pair of cricket extracts as an active ingredient.
  • the death rate of domestic liver disease is very high, 23.5 per 100,000 population.
  • the number of deaths in the 40s is the first (41.1 / 100,000), the second in the 50s (72.4 / 100,000) (10 people / 100,000 people), including liver disease is the leading cause of death in the Korean middle-aged population.
  • liver diseases fatty liver suggests that abnormal fat, which is not present in normal cells, is abnormally deposited in liver cells.
  • abnormal fat which is not present in normal cells, is abnormally deposited in liver cells.
  • triglyceride fatty acid, phospholipid, cholesterol and cholesterol ester are the main components of fat.
  • triglyceride fatty acid, phospholipid, cholesterol and cholesterol ester are the main components of fat.
  • triglyceride fatty acid, phospholipid, cholesterol and cholesterol ester
  • hepatocytes When the fatty liver becomes worse and fat mass in hepatocyte becomes larger, important components of the cells including nucleus are pushed to one side, the function of the hepatocyte is lowered, and the expanded hepatocytes due to the accumulated fat in the cells pressurize the microvascular and lymphatic vessels between the hepatocytes Resulting in obstacles to the circulation of blood and lymph in the liver. In this way, hepatocytes can not properly receive oxygen and nutrient supply, and liver function is deteriorated.
  • Non-alcoholic fatty liver disease is defined as the accumulation of fatty acids in the form of triglycerides in hepatocytes (5%) rather than in liver damage caused by alcohol. Pathologically, it is classified as simple steatosis and inflammatory fatty liver disease (steatohepatitis). It can be converted to severe liver disease such as hepatitis, liver fibrosis and cirrhosis when left for a long time. In Korea, the frequency of nonalcoholic liver disease is increasing due to changes in lifestyle.
  • Alcoholic fatty liver disease is caused by excessive alcohol consumption. Individuals have different genetic characteristics and gender. However, alcohol intake of 80g or more per day is very likely to cause liver disease such as alcoholic fatty liver disease. Women are more likely to develop alcoholic liver disease in lesser amounts. Generally, it can be calculated that one cup of shochu, one cup of beer, one cup of wine, and one cup of makkolli contain about 10 g of alcohol. The most mild form of alcoholic fatty liver disease is asymptomatic, but mild hepatic enlargement (greater than normal liver) may cause mild tenderness in the right upper abdomen.
  • Gryllus bimaculatus is a grasshopper species cricket, and it is an omnivorous species that feeds on grains, animal food, agricultural byproducts, etc., and has a short growth period of 90 days. . It is known to be runny at the time of the phytoplankton, and at night during the adult period. The eggs are transparent white, and they are scattered in the moist materials such as wet clay, sand, sawdust, and humus. Spawning uses a long ovipositor to lay eggs one deep in the spawning medium, giving birth to 100-200 eggs for a lifetime. Eggs start hatching when they develop for about 13 days at normal temperature.
  • Korean Patent No. 0599460 discloses a food containing a cricket extract having a preventive effect against hepatotoxicity.
  • a composition for prevention, improvement or treatment of a liver disease comprising the cricket extract of the present invention as an active ingredient is disclosed in There is no way.
  • the present invention provides a composition for preventing, ameliorating or treating a fatty liver disease comprising a cricket extract as an active ingredient, and the present invention provides a composition for preventing, The effect of reducing the triglyceride content and the weight change of the animal model by the cricket extract administration by pair; Weight change of liver, subcutaneous fat, kidney fat tissue and small intestine fat tissue; Confirming that lipid biochemical indicators change significantly, thus completing the present invention.
  • the present invention provides a health functional food composition for preventing or ameliorating fatty liver disease, which comprises a cricket extract of each pair as an active ingredient.
  • the present invention also provides a pharmaceutical composition for the prevention or treatment of fatty liver disease comprising a pair of cricket extracts as an active ingredient.
  • the present invention also provides a veterinary composition for the prevention or treatment of fatty liver disease in an animal other than a human, comprising a cricket extract of each pair as an active ingredient.
  • the present invention also provides a feed additive for preventing or ameliorating fatty liver disease in an animal other than a human, comprising a cricket extract of each pair as an active ingredient.
  • the present invention also provides a method of preventing or treating fatty liver disease comprising administering a pair of cricket extracts to an individual other than a human.
  • the present invention relates to a composition for preventing, ameliorating or treating a fatty liver disease comprising a pair of cricket extracts as an active ingredient.
  • the cricket extract of each pair which is an effective ingredient of the present invention, (HepG 2 ), and the weight change of the animal model according to the administration of the cricket extract by pair; Weight change of liver, subcutaneous fat, kidney fat tissue and small intestine fat tissue; Since changes in lipid biochemical indicators are significant, the composition of the present invention can be useful as a health functional food, a medicine, or a feed additive for prevention, improvement or treatment of fatty liver disease.
  • liver cancer cell line HepG 2 on oleate and palmitate
  • a 2: 1 concentration ratio of the free fatty acid and 1.0mM ssangbyeol Pass the cricket extract the content of triglycerides Nile Red (H depot red) mixed in the Dyed and measured.
  • FIG. 2 shows the results of measuring the content of total triglycerides after treating 1.0 mM free fatty acid and cricket fraction extracts mixed with hepatocellular carcinoma cell line (HepG 2 ) at a concentration ratio of 2: 1 of oleate and palmitate.
  • FIG. 3 shows results of measuring lipid uptake after treating 1.0 mM free fatty acid and cricket fraction extracts mixed with hepatocellular carcinoma cell line (HepG 2 ) at a concentration ratio of olate and palmitate of 2: 1.
  • #### indicates that the fat absorption rate was statistically significantly increased in the 1.0 mM free fatty acid-treated group compared with the negative control group without 1.0 mM free fatty acid treatment, which means that p ⁇ 0.0001 , *** and **** indicate that the fat absorption rate was significantly decreased in the group treated with free fatty acids and paired cricket extracts compared to the free fatty acid treatment group, *** was p ⁇ 0.001 , **** is p ⁇ 0.0001.
  • FIG. 4 shows the results of confirming cell viability (%) after treatment of hepatocellular carcinoma cell line (HepG 2 ) with ethanol and cricket extracts of each pair.
  • #### showed a statistically significant decrease in cell viability (%) in the 1.0 mM free fatty acid-treated group compared to the negative control (control) without treatment with 1.0 mM of free fatty acid, and p ⁇ 0.0001
  • **** indicates that the cell survival rate (%) was statistically significantly increased in the group treated with free fatty acids and paired cricket extracts compared to the free fatty acid treated group, and p ⁇ 0.0001.
  • FIG. 5 shows the results of confirming changes in the expression level of Caspase-3 after treatment of hepatocellular carcinoma cell line (HepG 2 ) with ethanol and a cricket extract of each pair.
  • control without 1.0 mM free fatty acid
  • #### showed a statistically significant increase in the relative Caspase-3 expression in the 1.0 mM free fatty acid-treated group, p ⁇ 0.0001, and **** indicates that the relative expression of Caspase-3 was significantly decreased in the group treated with free fatty acids and paired cricket extracts compared to the group treated with free fatty acids, and p ⁇ 0.0001 .
  • FIG. 6 shows the result of confirming that the body weight increased by the high-fat diet was reduced by the administration of the cricket extract of each pair.
  • FIG. 7 is a result of confirming that the liver, subcutaneous fat, kidney fat, and small intestine fat weight of the mice increased by the high fat diet decreased by administration of the cricket extract.
  • HFD high fat dietary group
  • SBG twin-specific cricket group
  • FIG. 8 shows the results of confirming that ALT and AST in the blood of the mice increased by the high-fat diet were decreased by the administration of the cricket extract.
  • ### and #### showed a statistically significant increase in the GPT (ALT) and GOT (AST) of the high fat diet group (HFD) compared to the normal diet group (Nor) **, ***, and **** were higher in the high fat diet group and the high fat fat diet group than in the high fat diet group (p ⁇ 0.0001) ** means p ⁇ 0.01, *** means p ⁇ 0.001, **** means p ⁇ 0.0001, and ** means that the amount of GPT (ALT) and GOT (AST) M100 is a positive control, milk seeds.
  • FIG. 9 shows the results of confirming that the concentration of triglyceride, total cholesterol, low density lipoprotein and free fatty acid in the blood of the mice increased by the high fat diet was decreased by the administration of the cricket extract.
  • HFD high fat dietary group
  • FIG. 10 shows the results of confirming that the blood glucose concentration of the mice increased by the high-fat diet was decreased by the administration of the cricket extract of each pair.
  • #### indicates a statistically significant increase in blood glucose concentration in the high-fat dietary group (HFD) compared to the normal diet (Nor), which means that p ⁇ 0.0001, ** and **** indicate high- (P ⁇ 0.01).
  • the mean serum glucose concentration was significantly lower in the group that consumed both the high fat diet and the cricket extract (SBG) than the high fat diet group 0.0 > p < 0.0001, < / RTI > M100 is a positive control, milk seed.
  • the present invention relates to a health functional food composition for preventing or ameliorating fatty liver disease comprising a cricket extract as an active ingredient.
  • the pair cricket extract may be prepared by a method including, but not limited to, the following steps:
  • step (3) The step of extracting the filtered extract of step (2) by concentration under reduced pressure and drying.
  • the extraction solvent is preferably selected from water, a C 1 -C 4 lower alcohol or a mixture thereof, more preferably a C 1 -C 4 lower alcohol, still more preferably 70% (v / v) ethanol, but is not limited thereto.
  • any conventional method known in the art such as filtration, hot water extraction, immersion extraction, reflux cooling extraction, and ultrasonic extraction may be used.
  • the extraction solvent is added by 1 to 20 times the weight of the dried cricket by dry weight, more preferably by 5 to 15 times.
  • the extraction temperature is preferably 4 to 50 ° C, but is not limited thereto.
  • the extraction time is preferably 0.5 to 10 hours, more preferably 0.5 to 5 hours, but not always limited thereto.
  • the drying is preferably performed under reduced pressure, vacuum drying, boiling, spray drying or freeze drying, but not always limited thereto.
  • the fatty liver disease is non-alcoholic or alcoholic simple fatty liver; Non-alcoholic or alcoholic fatty liver disease; And non-alcoholic or alcoholic cirrhosis, but is not limited thereto.
  • cricket extracts are characterized by reducing the content of triglyceride in liver tissue, reducing total triglyceride content in liver tissue and decreasing lipid uptake.
  • the health functional food may be prepared by adding the composition of the present invention to a food for the purpose of preventing or ameliorating fatty liver disease.
  • the health functional food is not particularly limited, and may be a health functional food, a nutritional supplement, but it can be any type of food such as pharmafood, health food, nutraceutical, designer food, food additive, etc.
  • the food can be meat, sausage, bread, chocolate, candy, snack, confectionery, , Other noodles, gums, dairy products including ice cream, various soups, drinks, tea, drinks, alcoholic beverages and vitamin complexes.
  • the method of adding is appropriately used according to a conventional method, and the amount to be added can be suitably determined according to the intended use (prevention, health or therapeutic treatment).
  • composition of the present invention may further include various components other than the active component.
  • the various components may be various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid, Salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks and the like. It may also contain flesh for the production of natural fruit juices, fruit juice beverages and vegetable beverages to add palatability and / or functionality, and these ingredients may be used independently or in combination.
  • the present invention also relates to a pharmaceutical composition for the prevention or treatment of fatty liver disease comprising a pair of cricket extract as an active ingredient.
  • the pharmaceutical compositions of the present invention may comprise a pharmaceutically acceptable carrier.
  • the pharmacologically acceptable carrier to be contained in the pharmaceutical composition of the present invention is one which is usually used at the time of formulation and includes saline, sterilized water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, But are not limited to, sucrose, sucrose, sucrose, sorbitol, mannitol, starch, acacia, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, syrup, methylcellulose, methylhydroxybenzoate, Hydroxybenzoate, talc, magnesium stearate and mineral oil, and the like.
  • the pharmaceutical composition of the present invention may further comprise an antioxidant, a buffer, a bacteriostatic agent, a diluent, a surfactant, a binder, a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifier, a suspending agent or a preservative.
  • the pharmaceutical composition of the present invention can be administered orally or parenterally, and is preferably administered orally.
  • the appropriate dosage of the pharmaceutical composition of the present invention may vary depending on such factors as formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, route of administration, excretion rate, .
  • the dosage of the pharmaceutical composition of the present invention is preferably 0.001-100 mg / kg on an adult basis.
  • the pharmaceutical composition of the present invention may be formulated into a unit dosage form by using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by those having ordinary skill in the art to which the present invention belongs. Or by intrusion into a multi-dose container.
  • the formulations may be in the form of solutions, suspensions, syrups or emulsions in oils or aqueous media, or in the form of excipients, powders, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.
  • the present invention also relates to a veterinary composition for preventing or treating fatty liver disease in an animal other than a human, which comprises a cricket extract as an active ingredient.
  • the veterinary compositions comprising the paired cricket extracts of the present invention may further comprise suitable excipients and diluents according to conventional methods.
  • excipients and diluents that can be included in the veterinary composition comprising the cricket extract of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin , Calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, cetanol, stearyl alcohol, Paraffin, sorbitan monostearate, polysorbate 60, methylparaben, propylparaben, and mineral oil.
  • the veterinary composition comprising the cricket extract according to the present invention may further include a filler, an anti-coagulant, a lubricant, a wetting agent, a spice, an emulsifier, an antiseptic, etc.
  • the veterinary composition according to the present invention may be administered after May be formulated using methods well known in the art to provide rapid, sustained or delayed release of the active ingredient, and the formulations may be formulated as powders, granules, tablets, capsules, suspensions, emulsions, solutions, syrups, aerosols, Soft or hard gelatine capsules, suppositories, sterile injectable solutions, sterile external preparations, and the like.
  • the veterinary composition according to the present invention may vary depending on the age, sex, and body weight of the animal, but may be administered in an amount of 0.1 to 100 mg / kg once or several times a day.
  • the dosage may vary depending on the route of administration, Sex, weight, age, and the like. Thus, the dosage amounts are not intended to limit the scope of the invention in any manner.
  • the present invention also relates to a feed additive for preventing or ameliorating fatty liver disease in an animal other than a human, comprising a cricket extract of each pair as an active ingredient.
  • the feed additive may be in the form of a high concentrate, powder or granule containing 20 to 90% by weight of cricket extract by pair.
  • the feed additive of the present invention can be used as a feed additive containing a phosphate such as citric acid, fumaric acid, adipic acid, lactic acid, malic acid, or organic acids such as sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate (polymerized phosphate), polyphenol, catechin, Natural antioxidants such as tocopherol, rosemary extract, vitamin C, green tea extract, licorice extract, chitosan, tannic acid, and phytic acid may be further included.
  • a phosphate such as citric acid, fumaric acid, adipic acid, lactic acid, malic acid, or organic acids such as sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate (polymerized phosphate), polyphenol, catechin, Natural antioxidants such as tocopherol, rosemary extract, vitamin C, green tea extract, licorice extract, chitosan, tannic acid, and phytic acid may be further included
  • the animal feed additives containing the cricket extracts of the present invention and the feeds containing the cricket extracts of the present invention can be used as auxiliary ingredients such as amino acids, inorganic salts, vitamins, antibiotics, antimicrobials, antioxidants, antifungal enzymes, digestion and absorption enhancers, And the like.
  • the feed additive may be administered alone to the animal in combination with other feed additives in the edible carrier.
  • the feed additives can also be easily administered as top dressing or they can be mixed directly with the animal feed or separately from the feed, in separate oral formulations, by injection or transdermal, or in combination with other ingredients.
  • a single daily dose or a divided daily dose can be used as is well known in the art.
  • the dosage form of the extract may be prepared in an immediate release or sustained release formulation in combination with a non-toxic pharmaceutically acceptable food carrier.
  • Such edible carriers may be solid or liquid, for example, corn starch, lactose, sucrose, soy flakes, peanut oil, olive oil, sesame oil and propylene glycol.
  • the dosage form of the extract may be a tablet, capsule, powder, troche or emulsion or top-dressing in finely divided form.
  • a liquid carrier it may be in the form of a soft gelatin capsule, or a syrup or liquid suspension, emulsion or solution.
  • the dosage form may contain adjuvants such as preservatives, stabilizers, wetting or emulsifying agents, solution promoting agents and the like.
  • the animal feed in which the paired cricket extract is included as a feed additive can be any protein-containing organic grain fraction commonly used to meet animal dietary needs. These protein-containing flours usually consist mainly of corn, soy flour or corn / soy flour mix.
  • the feed additive may be added to the animal feed by immersion, spraying or mixing.
  • the veterinary composition or feed additive of the present invention can be applied to the companion animal's diet.
  • the present invention also relates to a method of preventing or treating fatty liver disease comprising administering a pair of cricket extracts to an individual other than a human.
  • Such an individual includes all animals, including those with a possibility of fatty liver disease, including those suffering from fatty liver disease.
  • Liver cancer cell line (HepG 2) were purchased from ATCC (American Type Culture Collection). Streptomycin and cultured in a DMEM (Dulbecco's modified Eagle's medium ) containing the medium-liver cancer cell line (HepG 2) is 10% FBS, 1% penicillin. The cells were cultured in a 5% CO 2 incubator at 37 ° C, and the cells were divided into a number of cells (3 ⁇ 10 4 cells / 500 ⁇ l well) in a 24-well plate.
  • DMEM Dynabecco's modified Eagle's medium
  • crickets of each pair were extracted with 70% (v / v) ethanol to obtain an ethanol extract, and the ethanol extract was distilled under reduced pressure to obtain cricket ethanol extracts.
  • Example 4 Assessment of the content of triglycerides using nile red (AdipoRed staining) assay
  • FFA free fatty acids
  • AdipoRed solution prepared by dissolving 300 ⁇ l of AdipoRed in 10 ml of PBS
  • the plates were wrapped with aluminum foil to minimize photobleaching of the dye during this process.
  • Example 5 Determination of total triglyceride content and degree of lipid uptake according to treatment of cricket extracts by pair
  • liver cancer cell line (HepG 2) The processes of ethanol decreased cell viability and increase in Caspase-3 content is confirmed that the change happens in the process of the ssangbyeol cricket extract.
  • the cell survival rate was increased in a concentration dependent manner of the cricket extract by pair, and the expression level of Caspase-3 was remarkably decreased.
  • Example 7 Weight change of animal model by administration of cricket extract by pair; Liver, abdominal subcutaneous fat, kidney fat tissue and small intestine fat tissue; Analysis of lipid biochemical indicators
  • C57bl / 6Jj mice (mice) of 10 weeks of age were used in this Example 7, and male C57bl / 6Jj mice were fed from BioLink (Eumsung, Korea) for 7 weeks and adapted to the laboratory environment for 3 weeks. Mice with good health status were used in the experiment.
  • mice were fed with solid feed (antibiotics-free, Samyang Feed Co.) and water until the day of the experiment and maintained the environment of temperature 23 ⁇ 2 °C, humidity 55 ⁇ 15% (AIN-76A diet) and water were freely supplied and adapted to the laboratory environment. Then, 10-week-old mice with a good health condition were kept in a dark room at 23 ⁇ 2 ° C, humidity 55 ⁇ 15%, and 12 hours intervals with light on (07: 00 ⁇ 19: 00) SPF (Specific Pathogen Free) environment.
  • solid feed antibiotics-free, Samyang Feed Co.
  • mice were divided into two groups: normal control (Nor), high fat diet control (HFD, 60% fat), high fat diet group (100, 200mg / kg) (100 mg / kg) for 14 weeks. Water and the diet of each experimental group were fed freely, and the cricket extracts of each pair were orally administered for 14 weeks each day.
  • HFD high fat diet control
  • HFD 60% fat
  • high fat diet group 100, 200mg / kg
  • water and the diet of each experimental group were fed freely, and the cricket extracts of each pair were orally administered for 14 weeks each day.
  • the body weights of the experimental animals were measured and recorded for 14 weeks at a constant time every week. After 14 weeks, the experimental animals were divided into liver tissue weight, abdominal subcutaneous fat, small intestine fat and retroperitoneal adipose tissue And the weight of adipose tissue was calculated after extraction.
  • ALT and AST which are indicators of liver function in plasma separated from each experimental animal, triglyceride, total cholesterol , Low-density lipoprotein (LDL), free fatty acid, and blood sugar were measured using a biochemical automatic analyzer (Hitachi-720, Hitachi Medical, Japan).
  • the blood glucose concentration in the serum was increased by the high fat diet (HFD), but the blood glucose concentration in the group that consumed both the high fat diet and the twin cricket extract (SBG) decreased statistically significantly compared to the high fat diet group (FIG. 10) .

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Insects & Arthropods (AREA)
  • Nutrition Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition pour la prévention, le soulagement ou le traitement de la stéatose hépatique, comprenant un extrait de Gryllus bimaculatus en tant qu'ingrédient actif. Il a été confirmé que l'extrait de Gryllus bimaculatus, en tant qu'ingrédient actif de cette invention, réduit efficacement l'accumulation de triglycérides dans une lignée cellulaire du cancer du foie (HepG2) et, lors de administration, présente surtout des changements du poids corporel des modèles animaux, des changements du poids du foie, de la graisse sous-cutanée, du tissu adipeux rénal, et du tissu adipeux de l'intestin grêle, et des changements des indicateurs biochimiques lipidiques. De ce fait, la composition selon la présente invention peut être utilisée utilement en tant qu'aliments naturels fonctionnels, médicament ou additif alimentaire pour la prévention, le soulagement ou le traitement de la stéatose hépatique.
PCT/KR2018/007319 2017-06-30 2018-06-28 Composition pour la prévention, le soulagement ou le traitement de la stéatose hépatique, comprenant un extrait de gryllus bimaculatus en tant qu'ingrédient actif WO2019004733A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20170083129 2017-06-30
KR10-2017-0083129 2017-06-30
KR1020170181808A KR102085577B1 (ko) 2017-06-30 2017-12-28 쌍별귀뚜라미 추출물을 유효성분으로 포함하는 지방간 질환의 예방, 개선 또는 치료용 조성물
KR10-2017-0181808 2017-12-28

Publications (2)

Publication Number Publication Date
WO2019004733A2 true WO2019004733A2 (fr) 2019-01-03
WO2019004733A3 WO2019004733A3 (fr) 2019-03-28

Family

ID=64742457

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/007319 WO2019004733A2 (fr) 2017-06-30 2018-06-28 Composition pour la prévention, le soulagement ou le traitement de la stéatose hépatique, comprenant un extrait de gryllus bimaculatus en tant qu'ingrédient actif

Country Status (1)

Country Link
WO (1) WO2019004733A2 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100453575B1 (ko) * 2001-07-09 2004-10-20 대한민국 귀뚜라미 자체 또는 이의 추출물을 함유하는 간보호, 강장피로회복, 알코올대사 촉진, 과산화지질 생성 억제를 위한 식품조성물
KR100498809B1 (ko) * 2003-12-22 2005-07-01 대한민국 귀뚜라미 추출물을 함유하는 간보호 효과, 강장효과,알코올해독, 과산화지질 생성 억제용 약학적 조성물
KR101349136B1 (ko) * 2011-10-14 2014-01-29 대한민국 곤충 글라이코사미노글리칸을 유효성분으로 포함하는 지방간 또는 고지혈증 예방 또는 치료용 조성물
KR101708251B1 (ko) * 2014-12-18 2017-02-21 대한민국 귀뚜라미 분획물을 유효 성분으로 포함하는 간염 예방 및 치료용 조성물 및 간보호를 위한 식품조성물

Also Published As

Publication number Publication date
WO2019004733A3 (fr) 2019-03-28

Similar Documents

Publication Publication Date Title
US20100105766A1 (en) Composition for inhibition or prevention of bone density reduction
WO2019093739A1 (fr) Composition comprenant un extrait de ténébrion meunier en tant que principe actif, destinée à la prévention, à l'atténuation ou au traitement de la stéatose hépatique
KR101661145B1 (ko) 백편두 추출물을 유효성분으로 포함하는 비알콜성 지방간질환의 예방 또는 개선용 조성물
WO2018117659A1 (fr) Composition pharmaceutique comprenant un extrait de levis pulverata indigo ou une fraction de celui-ci comme principe actif pour prévenir ou traiter une maladie intestinale inflammatoire
JP2008174539A (ja) 紫色の馬鈴薯を使用した肥満患者用の健康機能食品
WO2023038350A1 (fr) Composition pour soulager le syndrome prémenstruel, contenant des souches de lactobacillus mélangées en tant que principe actif
WO2021201532A1 (fr) Composition de prévention, de soulagement ou de traitement du syndrome ménopausique chez la femme, contenant un extrait de rosa rugosa en tant que principe actif
WO2020059995A1 (fr) Composition de boisson diététique pour la prévention d'effets nocifs pour le foie provoqués par l'alcool tout en fournissant un excellent remède pour les effets secondaire causés par l'alcool
KR20190003304A (ko) 쌍별귀뚜라미 추출물을 유효성분으로 포함하는 지방간 질환의 예방, 개선 또는 치료용 조성물
WO2018093237A2 (fr) Composition comprenant de l'acide formique ou un sel pharmaceutiquement acceptable de celui-ci comme principe actif pour la prévention ou le traitement de l'obésité ou des syndromes métaboliques provoqués par l'obésité
WO2013047958A1 (fr) Composition pour inhiber une détérioration de la fonction hépatique, contenant un extrait d'écorce de citrus ou du narirutin comme ingrédient actif, et procédé pour extraire du narirutin à partir d'écorce de citrus
WO2023038258A1 (fr) Nouvelle souche lactobacillus gasseri lm1065 issue du lait maternel, et composition pour soulager le syndrome prémenstruel comprenant ladite souche ou son produit de culture
KR102041852B1 (ko) 벼메뚜기 추출물을 유효성분으로 포함하는 지방간 질환의 예방, 개선 또는 치료용 조성물
WO2018190630A1 (fr) Composition permettant la prévention, l'amélioration ou le traitement de maladies associées au syndrome des ovaires polykystiques comprenant un extrait d'ecklonia cava en tant que principe actif
WO2018030650A1 (fr) Composition anti-obésité contenant un extrait de feuilles de chrysanthème en tant que principe actif
WO2019004733A2 (fr) Composition pour la prévention, le soulagement ou le traitement de la stéatose hépatique, comprenant un extrait de gryllus bimaculatus en tant qu'ingrédient actif
WO2020122373A1 (fr) Composition comprenant un extrait de glycyrrhiza uralensis en tant que principe actif pour la prévention, l'atténuation ou le traitement du syndrome d'hypogonadisme d'apparition tardive
JP2014185088A (ja) 経口組成物、脂肪細胞分化抑制剤および飲食品
WO2019004734A2 (fr) Composition pour la prévention, le soulagement ou le traitement de la stéatose hépatique, comprenant un extrait d'oxya chinensis en tant qu'ingrédient actif
WO2019156335A1 (fr) Composition pharmaceutique destinée au traitement de la stéatose hépatique et aliment fonctionnel de santé destiné à l'amélioration de la fonction hépatique, les deux contenant un extrait ou une poudre de pleurotus eryngii var. ferulae en tant que principe actif
JP2005179235A (ja) ローヤルゼリー又はその処理物の水溶性画分から得られる特定の分子量画分を有効成分とする気分の障害の予防、治療又は改善用組成物
KR101373493B1 (ko) 톳을 유효성분으로 함유하는 비만 또는 고지혈증 및 동맥경화성 혈관계 질환의 예방 및 치료용 조성물
KR20160091045A (ko) 저속으로 추출한 석류주스를 유효성분으로 포함하는 간 기능 개선용 조성물
WO2023043218A1 (fr) Composition comprenant un extrait provenant de la masse cellulaire de bacillus subtilis natto pour améliorer la mémoire
WO2023008771A1 (fr) Composition destinée à prévenir, à soulager ou à traiter des troubles métaboliques, comprenant un extrait de passiflora caerulea

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18822679

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18822679

Country of ref document: EP

Kind code of ref document: A2